- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01879566
Effect of Catheter-based Radiofrequency Ablation Therapy in Patient With Therapy-resistant Hypertension and Sleep Apnea Syndrome
Effect of Catheter-based Radiofrequency Ablation Therapy of the Renal Sympathetic-Nerve System for Patient With Sleep Apnea Syndrome and Therapy Resistant Hypertension
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Contatti e Sedi
Luoghi di studio
-
-
ZH
-
Zurich, ZH, Svizzera, 8091
- University Hospital Zurich, Division of Cardiology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria: We plan to include male or female subjects, age 18-80 with a diagnosis of medium-severe sleep apnea syndrome (defined by symptoms, a complaint of excessive daytime sleepiness, an Epworth sleepiness score >8, and an apnea / hypopnea index >15/h) and a resistant hypertension (systolic blood pressure >140 mmHg or >130 mmHg in patients with type II diabetes or chronic kidney disease, under treatment with three antihypertensive drugs including a diuretic).
If the selected patients are treated with CPAP, this therapy should be stable during the whole study time.
Every patient will be asked for a written informed consent.
Exclusion criteria: - Heart failure (normal ejection fractions on echocardiography and no clinical signs and symptoms of heart failure).
- Long acting nitrates, or PDE-5-Hemmer
- Alcohol or drug abuse,
- Malignancy (unless healed or remission > 5 years)
- Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
- Pulmonary Hypertension (PAP>50 mmHg)
- Pregnancy
- Anatomical contraindication to renal denervation
- Know allergy to contrast
- Participation in another study within the last month
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in sympathetic nervous system activity (burst/min and burst/100 HB) before and after catheter-based radiofrequency ablation
Lasso di tempo: 6 and 12 months
|
The primary objective of this study is to evaluate sympathetic nervous system activity in patients with sleep apnea syndrome before and 6 and 12 months after catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system
|
6 and 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in 24-hour blood pressure (24 hour, day and night mean) before and after catheter-based renal denervation
Lasso di tempo: 1, 3, 6 12 months
|
Change in 24-hour blood pressure (24 hour, day and night mean) before and after catheter-based renal denervation
|
1, 3, 6 12 months
|
Change in renal function (creatinin plasma level and GFR CKD-EPI Formula) before and after catheter-based renal denervation
Lasso di tempo: 1, 3, 6, 12
|
Change in creatinin plasma level and GFR CKD-EPI Formula before and after catheter-based renal denervation
|
1, 3, 6, 12
|
Change in sleep quality, pulse-oximetry, AHI, quality of life and subjective sleepiness with the Epworth sleepiness score before after catheter-based renal denervation
Lasso di tempo: 1, 3, 6 and 12 months
|
1, 3, 6 and 12 months
|
|
Change in 24-hour Holter and heart rate variability, echocardiogramm before and after catheter-based renal denervation
Lasso di tempo: 6 and 12 months
|
6 and 12 months
|
|
Change in vascular function and oxidative stress and inflammation parameters before and after catheter-based renal denervation
Lasso di tempo: 1, 3, 6, and 12 months
|
Change in vascular function (endothelial function as flow mediated dilatation, arterial stiffness by pulse wave velocity) and oxidative stress and inflammation parameters before and after catheter-based renal denervation
|
1, 3, 6, and 12 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Thomas Luescher, Professor, MD, University Hospital Zurich, Division of Cardiology
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EK2012_0393
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .